Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;335 (14 July), doi:10.1136/bmj.39274.351389.3B
Douglas Kamerow, US editor
dkamerow@bmj.com
| The first 150 words of the full text of this article appear below. |
Do drug advertisements ("adverts" in Britspeak) belong in medical journals? In a head to head debate in this week's issue, Richard Smith, former BMJ editor and long-time critic of big pharma, says yes (doi: 10.1136/bmj.39259.472998.AD). He maintains, perhaps paradoxically, that advertising allows journals to be independent and thus better. Major journals have advertising from many manufacturers and thus no one company can exert undue pressure or influence. Smith's big concern is one that most readers don't even think about: the lucrative article reprints that journals sell for hundreds of thousands of dollars a year, largely to the drug companies whose products are evaluated in clinical trials published in the very same journals. Conflict of interest? You betcha.
Gareth Williams, University of Bristol's medical dean, argues against journal advertising of pharmaceuticals (doi: 10.1136/bmj.39259.481134.AD). He wants drug ads at least vetted for inaccuracy and misleading claims, but he would prefer
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?